Last10K.com

Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Ampio Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1411906 Ticker: AMPE
Document and Entity Information (USD $)
 12 Months Ended
Dec. 31, 2013
Feb. 12, 2014
Jun. 30, 2013
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2013    
Document Fiscal Year Focus 2013    
Document Fiscal Period Focus FY    
Trading Symbol AMPE    
Entity Registrant Name AMPIO PHARMACEUTICALS, INC.    
Entity Central Index Key 0001411906    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Common Stock, Shares Outstanding   42,134,332  
Entity Public Float     $ 161,591,937

View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ampio Pharmaceuticals, Inc..

Continue

Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity (deficit)
Consolidated Statements Of Stockholders' Equity (deficit) (parenthetical)
Acquisition Of Dmi Biosciences
Acquisition Of Dmi Biosciences (tables)
Acquisition Of Dmi Biosciences - Additional Information (detail)
Acquisition Of Dmi Biosciences - Summary Of Estimated Fair Value Of Net Assets Acquired At Acquisition Date (detail)
Asset Purchase Agreement/product Technology License
Asset Purchase Agreement/product Technology License - Additional Information (detail)
Business, Basis Of Presentation And Merger
Business, Basis Of Presentation And Merger - Additional Information (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Rent Expense (detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (detail)
Common Stock
Common Stock - Additional Information (detail)
Derivative Financial Instruments
Derivative Financial Instruments (tables)
Derivative Financial Instruments - Components Of Warrant Derivative Liability (detail)
Derivative Financial Instruments - Summary Of Income (expense) Associated With Changes In Fair Value Of Derivative Financial Instruments By Type Of Financing (detail)
Derivative Financial Instruments - Summary Of Unrealized Gain (loss) Associated With Hybrid Debt Instruments Recorded At Fair Value By Type Of Financing (detail)
Equity Instruments
Equity Instruments (tables)
Equity Instruments - Additional Information (detail)
Equity Instruments - Ampio Stock Option Activity (detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (detail)
Equity Instruments - Luoxis Stock Option Activity (detail)
Equity Instruments - Significant Assumptions (detail)
Equity Instruments - Summary Of Stock Based Compensation Expenses (detail)
Equity Instruments - Warrants Issued In Conjunction With Its Senior Convertible Debentures (detail)
Equity Instruments - Weighted Average Fair Value Per Share Granted (detail)
Fair Value Considerations
Fair Value Considerations (tables)
Fair Value Considerations - Financial Assets And Liabilities Accounted For At Fair Value On Recurring Basis (detail)
Fair Value Considerations - Reconciliation Of Changes In Fair Value Of Financial Assets And Liabilities Classified As Level Three (detail)
Fair Value Considerations - Significant Assumptions In Valuing Warrant Liability (detail)
Formation Of Subsidiaries
Formation Of Subsidiary - Additional Information (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Deferred Tax Assets And Liabilities (detail)
Income Taxes - Reconciliation Of Effective Tax Rate (detail)
License Agreement/revenue Recognition
License Agreement/revenue Recognition - Additional Information (detail)
Litigation
Litigation - Additional Information (detail)
Related Party Transactions
Related Party Transactions - Additional Information (detail)
Selected Quarterly Data (unaudited)
Selected Quarterly Data (unaudited) (tables)
Selected Quarterly Data (unaudited) - Selected Quarterly Results (detail)
Short Term Debt
Short Term Debt (tables)
Short Term Debt - Additional Information (detail)
Short Term Debt - Purchase Price Allocation Of Debentures (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Depreciation Expenses (detail)
Summary Of Significant Accounting Policies - Fixed Assets (detail)
Summary Of Significant Accounting Policies - Future Amortization Expense (detail)
Summary Of Significant Accounting Policies - Patents (detail)
Summary Of Significant Accounting Policies - Recorded Amortization Expense (detail)
Summary Of Significant Accounting Policies - Research And Development Costs (detail)
Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001193125-14-054391
Submitted to the SEC: Fri Feb 14 2014 2:56:33 PM EST
Accepted by the SEC: Fri Feb 14 2014
Period: Tuesday, December 31, 2013
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ampe/0001193125-14-054391.htm